• Crizanlizumab Lowers Pain Crises in At-risk Sickle Cell Patients, Ad-hoc Trial Data Show
  • Multi-Organization Partnership to Encourage Blood Donation and SCD Awareness
  • Agreement With Cardinal Health Widens Distribution of Endari for Emmaus
  • Advocacy Groups, Doctors Question Rising Prices of Rare Disease Treatments
  • #NORDSummit – More Than 700 Expected to Attend Oct. 15-16 Rare Disease Summit in Washington
  • IP-10 Could Be Biomarker of Inflammation in Pregnant Sickle Cell Patients, Study Reports
  • Sickle Cell Patients in UK Survey, Especially Those 16 to 20, Voice Problems with Care and Pain Relief Given
  • Activities Underway in US for Sickle Cell Disease Awareness Month
  • GlycA Seen as Not a Good Indicator of Inflammation in SCD Patients, Study Shows
  • Altemia Shows Promising Results in Phase 2 Trial for SCD Children
  • Emmaus Life Sciences Expands Distribution of Sickle Cell Disease Therapy, Endari
  • Roche Sells Cardio Antibody to GBT for Vaso-Occlusive Crises in SCD